O CEO da Arrowhead Pharmaceuticals vendeu uma participação de 1% na empresa, em meio a ganhos menores do que o esperado. Arrowhead Pharmaceuticals' CEO sold a 1% stake in the company, amid lower-than-expected earnings.

Christopher Anzalone, CEO da Arrowhead Pharmaceuticals, recentemente vendeu ações da empresa, reduzindo sua propriedade em cerca de 1%. Christopher Richard Anzalone, CEO of Arrowhead Pharmaceuticals, recently sold shares of the company's stock, reducing his ownership by about 1%. As transações foram divulgadas à SEC. The transactions were disclosed to the SEC. A Arrowhead Pharmaceuticals se concentra no desenvolvimento de medicamentos para doenças intratáveis e recentemente relatou ganhos trimestrais menores do que o esperado. Arrowhead Pharmaceuticals focuses on developing medicines for intractable diseases and recently reported lower-than-expected quarterly earnings. A empresa tem um valor de mercado de US $ 1,62 bilhão e analistas esperam que ela publique ganhos de -2,42 por ação no ano. The company has a market cap of $1.62 billion and analysts expect it to post earnings of -$2.42 per share for the year.